Lilly teams up with CureVac in $1.8 billion cancer vaccine partnership
pharmafile | October 19, 2017 | News story | Research and Development, Sales and Marketing | Cancer, CureVac, Eli Lilly, Vaccine
Eli Lilly has announced it is to partner up with CureVac to leverage its proprietary RNActive technology in order to develop and commercialise up to five cancer vaccine products.
The partnership is potentially worth up to $1.8 billion, broken down into an upfront payment of $50 million and an equity investment of $52.9 million. The remainder of the sum is comprised of development and commercial milestones for which CureVac is eligible, in addition to royalties on product sales. The full total will only be offered in the event all five vaccines are successfully developed.
“This new collaboration with Lilly is a testimony to the progress and sophistication of CureVac’s RNActive technology and the potential of mRNA-based therapeutics,” explained Dr Ingmar Hoerr, co-founder and CEO of CureVac. “We now have the opportunity to combine forces to further expand the exciting space of immuno-oncology with the next generation of cancer therapies. We are thrilled to work with the Lilly team and hope to advance this new treatment paradigm into the clinic and ultimately to the market.”
The partnership will utilise messenger RNA (mRNA) technology which is able to produce therapeutic proteins inside a patient’s body. CureVac’s technology works by employing specific tumour neoantigens which direct the patient’s immune system to attack cancer cells.
“We are excited to be collaborating with CureVac to discover what could potentially be the next frontier of cancer medicines,” said Dr Greg Plowman, Vice President of Oncology Research at Lilly. “This collaboration reinforces Lilly’s commitment to delivering life-changing medicines to treat and cure people living with cancer around the world.”
Matt Fellows
Related Content
BioNet receives positive EMA opinion on new pertussis vaccine
BioNet has received a positive opinion from the Committee for Medicinal Products for Human Use …
Recipharm offers manufacturing support to vaccine trial from ImmBIO and iiCON
Recipharm, a contract development and manufacturing organisation (CDMO), has successfully manufactured PnuBioVax, a new protein-based …
Lilly opens fourth US Gateway Labs site
Eli Lilly has opened its newest Lilly Gateway Labs (LGL) site in San Diego, California, …
